Dr Reddy’s launches BixiBat to treat chronic constipation in India
Elobixibat was approved by the CDSCO after submission of the company's successful Phase-3 clinical trial to the Subject Expert…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CDSCO
19th International Conference of Drug Regulatory Authorities commences in India
ICDRA is being hosted for the first time in India, bringing together regulatory authorities, policymakers, and health officials…
Capsules of controversy: India’s growing appetite for dietary supplements
The author highlights regulatory challenges and the growing risks in India's dietary supplements industry
CDSCO committee recommends Wockhardt’s novel antibiotic Miqnaf for CABP treatment
The recommendation clears the path for final approval from the DCGI following extensive clinical studies
The next industrial revolution in India will be driven by biotechnology
Dr Jitendra Singh noted that the number of biotech startups has risen from just 50 in 2014 to over 5,000 now, reflecting India’s…
CDSCO joins International Medical Device Regulators Forum as affiliate member
India’s CDSCO aligns with global medical device regulatory standards through IMDRF membership
Compliance, competition could be speed breakers
As India positions itself as part of the China+plus one strategy, China has a counter strategy: dumping of low cost imports and…
Critical to make a clear distinction between NSQ and Spurious Drugs: IPA
The association claims that the media has interchanged the terms “Not of Standard Quality” and “Spurious” in reports about a CDSCO…
Alkem Laboratories denies claims of substandard quality for Pan-D and Clavam 625
Company asserts that reported samples are spurious and not manufactured by Alkem
AstraZeneca India receives CDSCO approval for Durvalumab for specified additional indication
Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is…